Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 26

  • 1 276 clinical trials
  • 446 recruiting
  • 379 conditions
  • 28 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer327Asthma88Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV57COVID-1939Pulmonary arterial hypertension38Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Pneumonia32Small cell lung cancer32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza28Interstitial lung disease28Lung neoplasm malignant28Cystic fibrosis24Conjunctivitis allergic23Pulmonary hypertension23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 276 clinical trials

Small cell lung cancer extensive stage

Recruiting

Study on Maintenance Therapy with Durvalumab and Olaparib for Patients with Extensive Disease Small-Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:University Of Cologne

Bronchopulmonary dysplasia

Recruiting

Safety Study of Mesenchymal Cells for Preterm Infants with Bronchopulmonary Dysplasia

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Mesenchymal Cells
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal

Vocal fold immobility

Recruiting

Study on the Effectiveness of Autologous Adipose-Derived Stromal Vascular Fraction Cells for Patients with Scarred Vocal Folds

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Centre Hospitalier Regional De Marseille

Bronchopulmonary dysplasia

Recruiting

Study to Test if Zelpultide Alfa Helps Prevent Lung Disease in High-Risk Premature Babies

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Recombinant Human Surfactant Protein-D
  • Sponsor:Airway Therapeutics Inc.

Systemic sclerosis pulmonary

Recruiting

Study of rituximab and mycophenolate mofetil combination therapy compared to placebo for patients with interstitial lung disease related to systemic sclerosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Oesophageal carcinoma+3

Recruiting

Study on Changes in [18F]F-AraG Uptake After Radiotherapy in Patients with Non-Small Cell Lung Cancer, Melanoma, Breast Cancer, and Esophageal Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nelarabine
  • Sponsor:Amsterdam UMC Stichting

Cystic fibrosis

Recruiting

Study on Improving Bone Health in Children with Cystic Fibrosis Using Cholecalciferol

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Colecalciferol
  • Sponsor:Fakultni Nemocnice V Motole

Pulmonary embolism

Recruiting

Study of Catheter-Directed Thrombolysis Using Alteplase for Treatment of Intermediate-High Risk Acute Pulmonary Embolism

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Fakultni Nemocnice Kralovske Vinohrady

Non-small cell lung cancer stage III+3

Recruiting

Study of Volrustomig and Drug Combination for Patients with Early-stage Resectable Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Recruiting

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Hypoxia+2

Recruiting

Oxygen Therapy to Prevent Breathing Problems After Non-Cardiac Surgery in Patients at Risk for Postoperative Complications

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:65+ years
  • Substances:Oxygen
  • Sponsor:Medical University Of Graz

Staphylococcal infection+1

Recruiting

Study on the Safety of Inhaled Teicoplanin for Treating Staphylococcus aureus Infections in Cystic Fibrosis Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Teicoplanin
  • Sponsor:Azienda Ospedaliera Universitaria Integrata Verona

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin169 clinical trialsPembrolizumab145 clinical trialsCisplatin128 clinical trialsPemetrexed108 clinical trialsPaclitaxel80 clinical trialsDurvalumab71 clinical trialsAtezolizumab50 clinical trialsNivolumab49 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.